Sihuan Pharmaceutical Holdings Group Ltd 最近的每股盈餘為 $, $ 的預期。
Sihuan Pharmaceutical Holdings Group Ltd SHPHY 上一季度的收入表現如何?
Sihuan Pharmaceutical Holdings Group Ltd 上一季度的收入為 $
Sihuan Pharmaceutical Holdings Group Ltd 的收入預期是多少?
根據 位華爾街分析師的預測,Sihuan Pharmaceutical Holdings Group Ltd 的收入預期範圍從 $ 到 $
Sihuan Pharmaceutical Holdings Group Ltd 的盈利品質評分是多少?
Sihuan Pharmaceutical Holdings Group Ltd 的盈利品質評分為 /。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
Sihuan Pharmaceutical Holdings Group Ltd 何時發布財報?
Sihuan Pharmaceutical Holdings Group Ltd 的下一份財報預計在 2025-11-27 發布
Sihuan Pharmaceutical Holdings Group Ltd 的預期收益是多少?
根據華爾街分析師的預測,Sihuan Pharmaceutical Holdings Group Ltd 的預期收益為 $
Sihuan Pharmaceutical Holdings Group Ltd 是否超出收益預期?
Sihuan Pharmaceutical Holdings Group Ltd 最近的收益為 $, 預期。
關鍵數據
前收市價
--
開盤價
--
當日範圍
-
52週區間
-
交易量
--
平均成交量
--
股息收益率
--
每股盈餘 (TTM)
--
市值
--
什麼是 SIHUAN PHARMACEUTICAL HOLD GP L?
Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 2,767 full-time employees. The company went IPO on 2010-10-28. The firm operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The firm conducts its business in the domestic and overseas markets.